Mesoblast posts US$28 million Ryoncil revenue
Alpha Vantage · Simply Wall Street · · AI-summarised by FinFlash
Mesoblast reported US$28 million in Ryoncil revenue for Q1 FY26, alongside an 85% improvement in net operating cash spend and a US$99 million cash balance. The company said the results strengthen the investment narrative for its cell therapy platform and its potential to scale. Ryoncil remains central to Mesoblast's strategy.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.